Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms 1Meningioma 1Malignant Female Reproductive System Neoplasm 1Hemangiosarcoma 1Fallopian Tube Neoplasms 1Ependymoma 1Endometrial Neoplasms 1Disease Progression 1Colonic Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 14Leucovorin 12Fluorouracil 12Cetuximab 10Bevacizumab 9pembrolizumab 7Specimen Handling 7Nivolumab 6Magnetic Resonance Spectroscopy 6Irinotecan 5encorafenib 4Pemetrexed 4Gemcitabine 4Cisplatin 4fludarabine 3cemiplimab 3Laparoscopy 3Folfox protocol 3Early Intervention, Educational 3Cyclophosphamide 3Carboplatin 3Capecitabine 3Biopsy 3trifluridine tipiracil drug combination 2pertuzumab 2durvalumab 2dehydroftorafur 2aldesleukin 2X-Rays 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × neratinib × 90 days × Clear all
NCT03919292 2026-04-21

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Virginia Commonwealth University

Phase 1/2 Recruiting
83 enrolled
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡